ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Annovis Bio Inc

Annovis Bio Inc (ANVS)

28.23
0.00
(0.00%)
Closed February 10 3:00PM
28.23
0.00
( 0.00% )
Pre Market: 6:00PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
28.23
Bid
-
Ask
-
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
28.23
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
10,262,000
Dividend Yield
-
PE Ratio
-0.50
Earnings Per Share (EPS)
-5.48
Revenue
-
Net Profit
-56.2M

About Annovis Bio Inc

Annovis Bio Inc is a clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301. Annovis Bio Inc is a clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
-

ANVS Latest News

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative...

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative...

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative...

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative...

Annovis Bio, Inc. Announces Proposed Public Offering

MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative...

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for...

FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway

MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative...

Annovis to Host Year-End Investor Webcast on December 11, 2024

MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is...

Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)

MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative...

Annovis Bio Reports Third Quarter Financial Results and Provides Business Update

MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

ANVS - Frequently Asked Questions (FAQ)

What is the current Annovis Bio share price?
The current share price of Annovis Bio is US$ 28.23
How many Annovis Bio shares are in issue?
Annovis Bio has 10,262,000 shares in issue
What is the market cap of Annovis Bio?
The market capitalisation of Annovis Bio is USD 289.7M
What is the 1 year trading range for Annovis Bio share price?
Annovis Bio has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Annovis Bio?
The price to earnings ratio of Annovis Bio is -0.5
What is the reporting currency for Annovis Bio?
Annovis Bio reports financial results in USD
What is the latest annual profit for Annovis Bio?
The latest annual profit of Annovis Bio is USD -56.2M
What is the registered address of Annovis Bio?
The registered address for Annovis Bio is 1111B S GOVERNORS AVENUE, KENT, DOVER, DELAWARE, 19904
What is the Annovis Bio website address?
The website address for Annovis Bio is www.annovisbio.com
Which industry sector does Annovis Bio operate in?
Annovis Bio operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RLGTRadiant Logistics Inc
US$ 8.09
(14.75%)
22
RVPRetractable Technologies Inc
US$ 0.92
(13.43%)
51
CNLCollective Mining Ltd
US$ 6.70
(11.85%)
6
CVUCPI Aerostructures Inc
US$ 5.33
(11.74%)
74
AREAHarbor Alphaedge Next Generation Reits ETF
US$ 20.70
(11.61%)
8
CKXCKX Lands Inc
US$ 7.20
(-36.65%)
12
LGLLGL Group Inc
US$ 5.01
(-27.39%)
1
SVTServotronics Inc
US$ 8.01
(-26.00%)
1
AMBIAmbipar Emergency Response
US$ 4.11
(-18.29%)
1
AWXAvalon Holdngs Corp
US$ 3.01
(-9.88%)
19
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 26.99
(-1.32%)
1.27M
ETHU2x Ether ETF
US$ 4.40
(0.00%)
1.24M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
US$ 3.05
(1.16%)
915.51k
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF
US$ 2.86
(0.88%)
911.9k
SOXSDirexion Daily Semiconductor Bear 3X Shares New
US$ 20.41
(1.39%)
805.56k

Discussion

View Full Feed
Number sleven Number sleven 4 minutes ago
https://www.courtlistener.com/docket/18701895/amarin-pharma-inc-v-hikma-pharmaceuticals-usa-inc/
Sleven,
AMRN
arachnodude arachnodude 4 minutes ago
At this point, do you just copy and paste this same post every time production is moving forward, or do you manually type it out for the illusion of effort?

Let’s break this down—again:

“KBLB has not announced the initiation of production Cycle 5.”

And? B
KBLB
SC8 SC8 6 minutes ago
One can deny the facts all they want. Many times I've posted a partial lists of MK's lies, deceptions and examples of gross incompetence going back years, which no one can refute, as they're just facts per the public record. The guy is a proven serial liar and gross incompetent. It is what it is.
RDGL
IcyGalaxy60 IcyGalaxy60 6 minutes ago
Be patient, or go to crypto if you want fast money. This is long term investment.
NBRI
Sos28493 Sos28493 7 minutes ago
This the news that came out last week about vplm paying defendant fees?  What is different here?
VPLM
Nelson2 Nelson2 8 minutes ago
WTF happened!?
VSQTF
jour_trader jour_trader 8 minutes ago
This will just be Q3, Oct-Dec.  Annual 10K is end of June timing. 
ELTP
Invest-in-America Invest-in-America 8 minutes ago
SLQT: Was watching this yesterday too, behind their improved financials --- the RARE legitimate firm, with substantive news.
SLQT
tw0122 tw0122 8 minutes ago
.23s bought looking better this morning in the Casino lol
CNEY
patrik patrik 8 minutes ago
Yet we barely trade
Patrik
KBLB
JayB2022 JayB2022 8 minutes ago
I can't answer that. I think we get further guidance after the pilot program. I'm guessing Q2. Securing contracts is what the focus should be on. I'm feeling pretty confident on the pilots success. Not a solicitation to buy or sell. My opinions only. 
NTRR
EZ2 EZ2 9 minutes ago
Just remember...... Fidelity is a company too..... and " for profit " !   🤔
scortech scortech 10 minutes ago
Nobody wants your type of liquidity
CGAC
Jake731 Jake731 11 minutes ago
Good morning all. 




TPTW……!!!!!!!
TPTW
jay_tee jay_tee 11 minutes ago
Well logic tells me if he could still cash in 500k a year and not have to bother with shareholders, the sec, or paperwork and still cash in maybe more with another company he won't use common sense. If the bottom line doesn't benefit FOXO, we are screwed...
FOXO
cojoboy cojoboy 12 minutes ago
Do we make another run this week to 7's..???🤔🤔🤔🤔🤔
IGPK
SkeBallLarry SkeBallLarry 13 minutes ago
Good timing ... It's falling pretty-hard here also .. !! >

May not accumulate much as it is above freezing .. !!
uksausage uksausage 13 minutes ago
I bought in 2018 for under a buck
Sold the last in last couple of weeks for a profit!
Stupidly didn't sell and pay off my house in 2021 when over $50 but did get a nice car.
Have learned a lot about greed and unwillingness to pay tax!
Have to admit I should have paid more
PLUG
Here Today Here Today 13 minutes ago
Constant Failure To Delivers!!!!!
RNAZ
0210 0210 13 minutes ago
loadin' loading sooweeeter 9-10s...backin' up TANH loaded truck, lol.

Sea of Green Buys(asks slapped!!!), this am, hmmm...chk it out.
https://ih.advfn.com/stock-market/NASDAQ/tantech-TANH/trades
TANH
Furor Furor 14 minutes ago
Its something to worry about regarding the ELTP roadmap or status?
ELTP
georgie18 georgie18 14 minutes ago
STI...3994...🥳...DALLAS, Feb. 11, 2025 /PRNewswire/ -- Solidion Technology, Inc. (NASDAQ: STI), an advanced battery technology solutions provider, today announced that its technical team has filed several US patent applications on an innovative process for cost-effective production of graphe
STI
georgie18 georgie18 14 minutes ago
STI...3994...🥳...DALLAS, Feb. 11, 2025 /PRNewswire/ -- Solidion Technology, Inc. (NASDAQ: STI), an advanced battery technology solutions provider, today announced that its technical team has filed several US patent applications on an innovative process for cost-effective production of graphe
STI
MartinLutherKing MartinLutherKing 15 minutes ago
Beyond the $500B Stargate Project: The frontier of AI in oncology beckons

https://cancerletter.com/guest-editorial/20250124_3/#:~:text=This%20groundbreaking%20privately%20funded%20initiative,focus%20on%20%E2%80%9Ccuring%20cancer.%E2%80%9D
RNAZ